Glutamine-regulated VCP acetylation creates a proteostasis vulnerability in RB1-deficient tumor
Findings identify glutamine-regulated VCP acetylation as a metabolic–proteostasis dependency in RB1-deficient tumors and nominate VCP inhibition as a therapeutic strategy for this difficult-to-target tumor state.